Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists for hereditary angioedema (HAE), announced the acceptance of 12 abstracts for presentation at the 7th Bradykinin Symposium in Berlin, Germany, from September 5-6, 2024. The presentations include two oral presentations and ten poster presentations covering various aspects of their lead compound, deucrictibant.
The presentations will showcase clinical, real-world, nonclinical, and discovery data on deucrictibant, including its efficacy in HAE prophylaxis, treatment of HAE attacks, long-term safety, and cardiovascular safety. The symposium will also feature presentations on novel biomarker assays and preclinical models for bradykinin-mediated disorders.
Pharvaris (Nasdaq: PHVS), un'azienda biopharmaceutica in fase avanzata che sviluppa antagonisti orali del recettore B2 della bradichinina per l'angioedema ereditaria (HAE), ha annunciato l'accettazione di 12 abstract per la presentazione al 7° Simposio sulla Bradichinina che si terrà a Berlino, Germania, dal 5 al 6 settembre 2024. Le presentazioni includeranno due presentazioni orali e dieci presentazioni poster che coprono vari aspetti del loro composto principale, deucrictibant.
Le presentazioni metteranno in evidenza dati clinici, reali, non clinici e di scoperta su deucrictibant, compresa la sua efficacia nella profilassi dell'HAE, nel trattamento degli attacchi di HAE, la sicurezza a lungo termine e la sicurezza cardiovascolare. Il simposio presenterà anche relazioni su nuovi saggi biomarcatori e modelli preclinici per i disturbi mediati dalla bradichinina.
Pharvaris (Nasdaq: PHVS), una compañía biofarmacéutica en etapa avanzada que desarrolla antagonistas orales del receptor B2 de bradiquinina para el angioedema hereditario (HAE), anunció la aceptación de 12 resúmenes para ser presentados en el 7.º Simposio de Bradiquinina en Berlín, Alemania, del 5 al 6 de septiembre de 2024. Las presentaciones incluirán dos presentaciones orales y diez presentaciones en cartel que cubren varios aspectos de su compuesto principal, deucrictibant.
Las presentaciones exhibirán datos clínicos, en el mundo real, no clínicos y de descubrimiento sobre deucrictibant, incluida su eficacia en la profilaxis del HAE, el tratamiento de los ataques de HAE, la seguridad a largo plazo y la seguridad cardiovascular. El simposio también contará con presentaciones sobre nuevos ensayos de biomarcadores y modelos preclínicos para trastornos mediadas por bradiquinina.
Pharvaris (Nasdaq: PHVS)는 유전성 혈관 부종 (HAE)을위한 구강 브래디키닌 B2 수용체 길항제를 개발하는 후기 단계의 생명공학 회사로, 2024 년 9 월 5 일부터 6 일까지 독일 베를린에서 열리는 제 7 회 브래디키닌 심포지엄에서 12 개 초록 발표를 수락했다고 발표했습니다. 발표에는 두 개의 구두 발표와 열 개의 포스터 발표가 포함되어 있으며, 이들은 그들의 주요 화합물인 deucrictibant의 다양한 측면을 다룹니다.
발표에서는 HAE 예방에서의 효능, HAE 공격 치료, 장기 안전성 및 심혈관 안전성을 포함한 deucrictibant의 임상, 실제, 비임상 및 발견 데이터를 보여줄 예정입니다. 심포지엄은 또한 브래디키닌 매개 장애를 위한 새로운 바이오마커 분석 및 전임상 모델에 대한 발표를 특징으로 할 것입니다.
Pharvaris (Nasdaq: PHVS), une entreprise biopharmaceutique en phase avancée développant des antagonistes oraux des récepteurs B2 de bradykinine pour l'angioedème héréditaire (HAE), a annoncé l'acceptation de 12 résumés pour présentation au 7ème Symposium sur la Bradykinine à Berlin, Allemagne, du 5 au 6 septembre 2024. Les présentations comprendront deux présentations orales et dix présentations par affiches couvrant divers aspects de leur composé principal, deucrictibant.
Les présentations mettront en avant des données cliniques, sur le terrain, non cliniques et de découverte concernant le deucrictibant, y compris son efficacité dans la prophylaxie de l'HAE, le traitement des attaques d'HAE, la sécurité à long terme et la sécurité cardiovasculaire. Le symposium comportera également des présentations sur de nouveaux tests de biomarqueurs et des modèles précliniques pour les troubles médiés par la bradykinine.
Pharvaris (Nasdaq: PHVS), ein Unternehmen für biopharmazeutische Entwicklungen in der späten Phase, das orale Bradykinin B2-Rezeptor-Antagonisten zur Behandlung von hereditärem Angioödem (HAE) entwickelt, gab die Annahme von 12 Abstracts zur Präsentation auf dem 7. Bradykinin-Symposium in Berlin, Deutschland, am 5. und 6. September 2024 bekannt. Die Präsentationen umfassen zwei mündliche Vorträge und zehn Posterpräsentationen, die verschiedene Aspekte ihres Hauptprodukts, deucrictibant, abdecken.
Die Präsentationen werden klinische, reale, nichtklinische und Entdeckungsdaten zu deucrictibant zeigen, einschließlich der Wirksamkeit bei der HAE-Prophylaxe, der Behandlung von HAE-Anfällen, der Langzeitsicherheit und der kardiovaskulären Sicherheit. Das Symposium wird auch Präsentationen zu neuartigen Biomarker-Assays und präklinischen Modellen für bradykininvermittelte Erkrankungen beinhalten.
- Acceptance of 12 abstracts for presentation at a major scientific symposium
- Data presentations covering multiple aspects of deucrictibant's efficacy and safety
- Inclusion of long-term safety and efficacy data for HAE prophylaxis
- Presentation of real-world data comparing deucrictibant to standard of care
- None.
ZUG, Switzerland, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for oral presentation and ten abstracts for poster presentation at the upcoming 7th Bradykinin Symposium, to be held from September 5-6, 2024, in Berlin, Germany. Presentation details are as follows:
- Title: Bradykinin Challenge Model in Humanized Bradykinin B2 receptor Transgenic Rat
Presenter: Jolanta Skarbaliene, Ph.D.
Format: Oral Presentation, Session II
Date, time: Thursday, Sept. 5, 15.05-15.15 CEST (9:05-9:15 a.m. EDT)
- Title: Prophylactic Treatment with Deucrictibant Improves HAE Disease Control and HRQoL
Presenter: Markus Magerl, M.D.
Format: Oral Presentation, Session VII
Date, time: Friday, Sept. 6, 15.05-15.15 CEST (9:05-9:15 a.m. EDT)
- Title: Long-Term Safety and Efficacy of Oral Deucrictibant for HAE Prophylaxis
Presenter: Marc A. Riedl, M.D., M.S.
Format: Poster Presentation
Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
- Title: Treatment of HAE Attacks with Oral Deucrictibant: RAPIDe-2 Extension Results
Presenter: Emel Aygören-Pürsün, M.D.
Format: Poster Presentation
Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
- Title: Prophylaxis of Hereditary Angioedema Attacks with Oral Deucrictibant: CHAPTER-1 Results
Presenter: Emel Aygören-Pürsün, M.D.
Format: Poster Presentation
Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
- Title: Deucrictibant vs. Standard of Care in HAE: Propensity Score-Matched Analysis
Presenter: Marc A. Riedl, M.D., M.S.
Format: Poster Presentation
Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
- Title: Clinical Trials Conformity with AURORA COS: a systematic literature review
Presenter: Remy Petersen, M.D., Ph.D.
Format: Poster Presentation
Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
- Title: Cardiovascular safety of repeated oral administration of the B2 receptor antagonist deucrictibant
Presenter: Nieves Crespo, Ph.D.
Format: Poster Presentation
Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
- Title: The bradykinin challenge model translates across rat, monkey and human
Presenter: Juan Bravo, Ph.D.
Format: Poster Presentation
Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
- Title: Deucrictibant inhibits carrageenan-induced edema in bradykinin B2 receptor transgenic rat
Presenter: Anne Lesage, Ph.D.
Format: Poster Presentation
Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
- Title: A novel kinin biomarker assay for characterization of bradykinin-mediated disorders
Presenter: Evangelia Pardali, Ph.D.
Format: Poster Presentation
Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
- Title: A HMWK capillary immunoblotting assay to characterize bradykinin-mediated disorders
Presenter: Evangelia Pardali, Ph.D.
Format: Poster Presentation
Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
Upon lift of the embargo, the presentation slides and posters will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations.
About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all types of HAE effective, well-tolerated, and easy-to-administer alternatives to treat attacks, both in the prophylactic and on-demand setting. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is encouraged to further develop deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the on-demand treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks in the coming months. For more information, visit https://pharvaris.com/.
FAQ
What is the main focus of Pharvaris' presentations at the 7th Bradykinin Symposium?
How many abstracts from Pharvaris (PHVS) were accepted for the 7th Bradykinin Symposium in 2024?
When and where will the 7th Bradykinin Symposium featuring Pharvaris' (PHVS) presentations take place?
What specific data on deucrictibant will Pharvaris (PHVS) present at the 2024 Bradykinin Symposium?
